William Blair Investment Management LLC reduced its holdings in Humana Inc. (NYSE:HUM – Free Report) by 9.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,854 shares of the insurance provider’s stock after selling 3,307 shares during the period. William Blair Investment Management LLC’s holdings in Humana were worth $11,773,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Johnson Financial Group Inc. acquired a new position in shares of Humana during the 2nd quarter worth about $26,000. Trust Co. of Vermont bought a new position in shares of Humana in the 2nd quarter valued at about $28,000. Bogart Wealth LLC increased its position in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after acquiring an additional 48 shares during the last quarter. MidFirst Bank acquired a new stake in shares of Humana in the second quarter valued at about $35,000. Finally, Highland Investment Advisors LLC acquired a new stake in shares of Humana in the second quarter valued at about $43,000. 92.38% of the stock is owned by institutional investors.
Humana Trading Up 0.1%
Humana stock opened at $450.38 on Monday. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $456.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The stock has a market capitalization of $54.09 billion, a P/E ratio of 43.81, a PEG ratio of 2.14 and a beta of 0.65. The stock has a 50-day simple moving average of $408.53 and a 200 day simple moving average of $316.91.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts expect that Humana Inc. will post 9.66 earnings per share for the current year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana’s payout ratio is currently 34.44%.
Insider Buying and Selling at Humana
In related news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the transaction, the insider directly owned 21,910 shares of the company’s stock, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Monness Crespi & Hardt upgraded Humana to a “buy” rating in a report on Friday, October 9th. Zacks Research raised Humana from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 10th. HSBC cut shares of Humana to a “hold” rating in a research note on Thursday, July 30th. Cantor Fitzgerald boosted their target price on shares of Humana from $460.00 to $495.00 and gave the stock an “overweight” rating in a report on Monday, November 9th. Finally, Lake Street Capital assumed coverage on shares of Humana in a research report on Thursday, July 30th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $476.52.
Check Out Our Latest Research Report on Humana
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Read More
- Five stocks we like better than Humana
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
